Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Pharmacology

Background:

• Cardiovascular disease is a leading global cause of mortality.
• Hypercholesterolemia is a significant risk factor for cardiovascular disease.
• PCSK9 (proprotein convertase subtilisin/kexin type 9) is a key therapeutic target for managing hypercholesterolemia.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in PCSK9 inhibition strategies.
• To discuss various therapeutic approaches targeting PCSK9 for hypercholesterolemia treatment.
• To explore both direct inhibition and expression suppression methods for PCSK9.

Main Methods:

• Review of current scientific literature on PCSK9 inhibition.
• Analysis of therapeutic strategies including protein-protein interaction disruption, gene silencing, and novel approaches.
• Examination of peptidomimetics, adnectins, monoclonal antibodies, small molecules, siRNA, genome editing, active vaccination, and heparin mimetics.

Main Results:

• Multiple therapeutic avenues exist for PCSK9 inhibition.
• Strategies focus on blocking PCSK9-LDLR interaction or reducing PCSK9 expression.
• Emerging methods like active vaccination and heparin mimetics offer alternative treatment pathways.

Conclusions:

• PCSK9 inhibition is a promising strategy for hypercholesterolemia and cardiovascular disease management.
• A range of innovative therapeutic approaches are under development.
• Further research into these diverse strategies holds potential for improved patient outcomes.